focus -WSS

focus

author：comprehensive 2025-08-26 23:44:24 - browse：14695

An advisory committee to the Food and Drug Administration will convene on Tuesday to evaluate the benefits of renal denervation, a one-time surgical procedure that works to reduce blood pressure. The promise — and the potential market — is enormous, but the data on how well the procedure works remains contentious.

The committee will evaluate data from two companies vying for market approval: ReCor Medical, a startup owned by Japanese company Otsuka Medical Devices, and device giant Medtronic, both of which have made surgical systems to treat hypertension.

Data from an analysis of three randomized clinical trials of ReCor Medical’s device showed a modest decrease in blood pressure after two months compared to a control group that received a placebo procedure. Medtronic’s late-stage trial showed that renal denervation reduced hypertension when measuring blood pressure in the doctor’s office, but did not show a reduction in blood pressure when patients measured it at home over 24 hours. At-home blood pressure is considered the more accurate measure, as blood pressure levels tend to artificially rise with anxiety in the clinic. Neither study presented serious safety concerns.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： HHS names first

WSS

Risky weight loss products often used by teens globally, per study

Doulas covered by Medicaid under New York's new plan

Will the market for weight loss drugs really reach $100 billion?

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

JPM 2024: Nvidia claims we're in biological revolution. Are we?

What don’t we know about an Alzheimer’s drug side effect?

entertainment

focus

explore

BioMarin wins approval for gene therapy to treat hemophilia A

Generative AI mines health records to identify patients’ social needs

Virginia high school admissions case could be legal follow

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Heart disease and mental health: A look at cardiac psychology

Bright Health sells Medicare Advantage business to Molina

Health and fitness trackers are measuring the wrong things

Psychedelics group wrestles with new pharma identity

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Wikipedia

Designating disabled people as health disparity population is crucial

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

New menopause drug shows promise in relief for hot flashes

JPM 2024: Nvidia claims we're in biological revolution. Are we?

As biotech industry slumps, bioscience job market is upside down

UnitedHealth’s Optum accused of antitrust violations in California

leisure time

entertainment

focus

focus